2023 Right Heart Symposium

This program is no longer being offered with credits as it has expired. To view presentations, to to Videos section and click on each session.

Program Description

Pulmonary vascular disease (PVD), including pre- and post-capillary pulmonary hypertension, is a spectrum of progressive, symptomatic, and ultimately fatal disorders for which significant advances in treatment have been made. Despite advances in the management of PVD, the mortality rate remains disproportionate. Evaluation and treatment are often delayed until patients present with serious complications. Effective management requires timely recognition, accurate diagnosis, and selection of the different therapeutic options. 

Progression to right ventricular dysfunction and finally failure can occur as an acute event in consequences where the pulmonary hypertension develops acutely as with pulmonary embolism, or because of a chronic condition such as pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD), interstitial lung disease, or chronic left sided heart or valvular disease.

Early detection and appropriate management can improve quality of life and may improve survival. Medical therapy has come a long way towards decreasing symptoms, enhancing performance, and improving prognosis, but there is still a long way to go, especially for the broader population of patients with PVD.

This program is tailored to clinical and research professionals who study and/or care for patients with right heart disease, congenital heart disease, pulmonary hypertension, and associated disorders.

At the end of this program, participants should be able to:

1. Review the options for advanced imaging approaches to assess and monitor RV function and pulmonary vascular remodeling

2. Describe pharmacologic interventions to augment or restore RV function in the patient with advanced PVD or critical illness

3. Assess the latest interventional, device, and pharmacologic approaches to PVD and evaluate these options in various forms of PVD, including disease-modifying pathways such as PDGF and TGF-beta signaling

4. Discuss advanced hemodynamic and physiologic correlates of right ventricular-pulmonary arterial coupling

Videos

Session 1: Assessing RV Function and Response to Treatment – Moderated by Jane A. Leopold, MD and Aaron B. Waxman, MD, PhD

Session 2: The Failing Right Heart – What Are the Realistic Salvage Options? – Moderated by Eileen M. Harder, MD, Alexandra K. Wong, MD, and Marius Hoeper, MD

Session 3: The Art of Hemodynamics – What does the RHC Really Tell Us? – Moderated by Anton Vonk Noordegraaf, MD, PhD, Bradley Wertheim, MD, and Jane Leopold, MD

Session 4: Pulmonary Embolism – Moderated by Alexandra K. Wong, MD and Farbod N. Rahaghi, MD, PhD

Session 5: Novel Interventional and Pharmaceutical Approaches – Moderated by Aaron B. Waxman, MD, PhD, Bradley M. Wertheim, MD, and Harrison Farber, MD

Session 6: Pulmonary Non-Hypertensive Vascular Pathology – Moderated by Stephanie Perella, PA-C and Charlie Lee, PA-C

Event Agenda

Day 18:00-8:10 AMWelcome RemarksAssessing RV Function and Response to Treatment – Moderated by Jane A. Leopold, MD and Aaron B. Waxman, MD, PhD8:10-10:15 AMAssessing the RV: It’s All in the Curves – Francois Haddad, MDAssessing the RV: It’s the Dots, Not the Curves: Focus on Speckle Tracking and Strain Imaging – Monica Mukherjee, MD, MPHIs There a Role for PET or Molecular Imaging to Assess the RV? – Paul B. Yu, MD, PhDAdvanced Imaging Approaches to Assessing Pulmonary Vascular Remodeling and RV Function – Farbod N. Rahaghi, MD, PhDPanel Discussion10:15-10:30 AMBreakThe Failing Right Heart – What Are the Realistic Salvage Options? – Moderated by Eileen M. Harder, MD, Alexandra K. Wong, MD, and Marius Hoeper, MD10:30 AM-12:00 PMVasopressor Support in RH Failure – Can We Optimize RV Mechanics and Coronary Perfusion? – Bradley M. Wertheim, MDInotropic Support in RV Failure – Is There Really a Role? – Hilary M. DuBrock, MDWhen to Consider MCS – Hemodynamic, Physiologic, and Patient Selection – Manreet K. Kanwar, MDWhen and why is the RV too Sick for Lung Transplantation? – Nirmal S. Sharma, MDPanel discussion12:00-1:00 PMLunch BreakKEYNOTE PRESENTATION1:00-1:50 PMAssessing Right Ventricular Function Using Exercise, Imaging, and Hemodynamics – Anton Vonk Noordegraaf, MD, PhD1:50-2:00 PMBreakThe Art of Hemodynamics – What does the RHC Really Tell Us? – Moderated by Anton Vonk Noordegraaf, MD, PhD, Bradley Wertheim, MD, and Jane Leopold, MD2:00-5:00 PMRV-PA Coupling, Afterload, and Pressure-Volume Curves – Paul Heerdt, MD, PhDPulmonary Artery Hemodynamics: the Action is in the Proximal Vasculature – Franz Rischard, DO, MScPulmonary Artery Hemodynamics: the Action is in the Small Vessels – Inderjit Singh, MD, FRCPClinical Implications of Aggressive Afterload Reduction – Eileen M. Harder, MDPanel discussionDay 28:00-8:10 AMWelcome Remarks and AnnouncementsPulmonary Embolism – Moderated by Alexandra K. Wong, MD and Farbod N. Rahaghi, MD, PhD8:10-9:45 AMClot In Transit – What is the Optimal Approach? – Gregory Piazza, MD, MSWhat does Clot Burden Mean? – Josanna Rodriguez-Lopez, MDProvoked and Unprovoked – What is the Difference, and does it Matter? – Behnood Bikdeli, MD, MSOptimal Duration of Anticoagulation – 2 months; 3 months; life long? – Alison Witkin, MDPanel discussion9:45-10:00 AMBreakNovel Interventional and Pharmaceutical Approaches – Moderated by Aaron B. Waxman, MD, PhD, Bradley M. Wertheim, MD, and Harrison Farber, MD10:00 AM-12:00 PMIntrapulmonary Artery Balloon Pump – Why and When? – Jane A. Leopold, MDTargeting BMPR2 – Marius Hoeper, MDTargeting Metabolism – is it a Viable Target? – Sebastien Bonnet, PhDIn the Age of Disease Modifiers, What Should our Approach to Treatment be? – Roham T. Zamanian, MDPanel discussion12:00-1:00 PMLunch BreakPulmonary Non-Hypertensive Vascular Pathology – Moderated by Stephanie Perella, PA-C and Charlie Lee, PA-C1:00-2:45 PMPulmonary AVM’s without HHT – Alexandra K. Wong, MDAnomalous Venous Return – Diagnosis and Management – Ada Stefanescu Schmidt, MD, MsCLeft to Right Shunting and Enhanced Pulmonary Blood Flow – Why is the Patient Dyspneic? – Phillip Joseph, MDPulmonary Artery Aneurysm – is it a Surgical Disease? – Harrison Farber, MDPanel discussion2:45 PMClosing Remarks

Sponsorship Information

GOLD SPONSORS

United Therapeutics Corporation

SILVER SPONSORS

Janssen Pharmaceuticals
Merck
Pharmosa Biopharm Inc.

START-UP SPONSORS

Aria CV
OrphAI Therapeutics
Liquidia

Accreditation

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and North American Thrombosis Forum. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Contact Hours: 12.75

Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation

Planning Committee

Aaron B. Waxman, MD, PhDJane Leopold, MDAlexandra Wong, MDBradley Wertheim, MDCharlie Lee, PA-CDeborah Whalen, APRN, MSNEileen Harder, MDFarbod Rahaghi, MD, PhDStephanie Perella, PA-C